<DOC>
	<DOCNO>NCT00003131</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness CMA-676 treating patient acute myeloid leukemia first relapse .</brief_summary>
	<brief_title>CMA-676 Treating Patients With Acute Myeloid Leukemia First Relapse</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy CMA-676 term number patient acute myeloid leukemia attain complete remission . II . Assess safety CMA-676 patient population . OUTLINE : This open label , single arm , multicenter study . Patients receive CMA-676 IV 2 hour day 1 . Patients may receive 1 additional dose therapy 15 28 day later . Patients achieve complete morphologic remission follow additional 6 month every 3-6 month thereafter relapse and/or death . PROJECTED ACCRUAL : 55 evaluable patient accrue . Enrollment extend additional 55 patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose CD33 positive acute myeloid leukemia ( AML ) first relapse At least 6 month complete remission No CNS leukemia No AML secondary exposure chemotherapy toxins PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC le 30,000/mm3 time CMA676 administration Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No severe cardiac disease Pulmonary : No severe pulmonary disease Other : Not pregnant nursing Fertile patient must use effective method contraception Not know HIV positive No prior myelodysplastic syndrome No active malignancy No uncontrolled infection Able obtain bone marrow aspirate PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation No prior antiCD33 antibody therapy Chemotherapy : No prior chemotherapy AML first relapse except hydroxyurea At least 24 hour since prior hydroxyurea Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>